AR037145A1 - Compuestos de 6,7-dihidro-5h-pirazolo[1,2-a]pirazol-1-onas, composicion farmaceutica que los comprende y uso para fabricar un medicamento para controlar citoquinas inflamatorias - Google Patents
Compuestos de 6,7-dihidro-5h-pirazolo[1,2-a]pirazol-1-onas, composicion farmaceutica que los comprende y uso para fabricar un medicamento para controlar citoquinas inflamatoriasInfo
- Publication number
- AR037145A1 AR037145A1 ARP020103548A ARP020103548A AR037145A1 AR 037145 A1 AR037145 A1 AR 037145A1 AR P020103548 A ARP020103548 A AR P020103548A AR P020103548 A ARP020103548 A AR P020103548A AR 037145 A1 AR037145 A1 AR 037145A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- hydrogen
- alkyl
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000002757 inflammatory effect Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 125000005275 alkylenearyl group Chemical group 0.000 abstract 1
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Compuestos, sus formas enantioméricas y diastereoméricas y sales farmacéuticamente aceptables, que tienen la fórmula (1), donde: R es -O[CH2]kR3 o -NR4aR4b; R3 es alquilo C1-4 sustituido o no sustituido, hidrocarbilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, arilo o alquilenarilo sustituido o no sustituido, heteroarilo o alquilenheteroarilo sustituido o no sustituido; el índice k es 0 a 5; R4a y R4b independientemente cada uno son: hidrógeno; o -[C(R5aR5b)]mR6; cada R5a y R5b independientemente son hidrógeno, -OR7, -N(R7)2, -CO2R7, -CON(R7)2; alquilo C1-4 lineal, ramificado, o cíclico, y mezclas de éstos, R6 es hidrógeno, -OR7, -N(R7)2, -CO2R7, -CON(R7)2; alquilo C1-4 sustituido o no sustituido, heterocíclico, sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido R7 es hidrógeno, un catión soluble en agua, o alquilo C1-4; o arilo sustituido o no sustituido, el índice m es de 0 a 5; R1 es: arilo sustituido o no sustituido; o heteroarilo sustituido o no sustituido; cada unidad R2 es hidrógeno; -(CH2)jO(CH2)nR8; -(CH2)jNR9aR9b; -(CH2)jCO2R10; -(CH2)jOCO2R10, -(CH2)jCON(R10)2; -(CH2)jOCON(R10)2; dos unidades R2 pueden formar juntas una unidad de carbonilo; y mezclas de éstos; R8, R9a, R9b, y R10 independientemente cada uno son hidrógeno, alquilo C1-4 y mezclas de éstos; R9a y R9b pueden formar juntos un anillo carbocíclico o heterocíclico que comprende de 3 a 7 átomos; dos unidades R10 pueden formar juntos un anillo carbocíclico o heterocíclico que comprende de 3 a 7 átomos; j es un índice de 0 a 5; n es un índice de 0 a 5; Z es O, S, NR11, o NOR11; R11 es hidrógeno o alquilo C1-4. Composición farmacéutica que comprende dichos compuestos y uno o más excipientes farmacéuticamente aceptables. Uso para fabricar un medicamento para controlar la liberación extracelular de citoquinas inflamatorias, en casos de artritis reumatoide, osteoartritis, enfermedad inflamatoria del intestino, choque séptico y otras.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32362501P | 2001-09-20 | 2001-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037145A1 true AR037145A1 (es) | 2004-10-27 |
Family
ID=23259997
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103549A AR037502A1 (es) | 2001-09-20 | 2002-09-20 | Compuesto de 6,7-dihidro-5h-pirazolo[1,2a]pirazol-1-ona espirociclico y su uso para fabricar una composicion farmaceutica |
| ARP020103550A AR037237A1 (es) | 2001-09-20 | 2002-09-20 | Compuesto de pirazolo de anillo fusionado, composicion que lo comprende y su uso para fabricar dicha composicion |
| ARP020103548A AR037145A1 (es) | 2001-09-20 | 2002-09-20 | Compuestos de 6,7-dihidro-5h-pirazolo[1,2-a]pirazol-1-onas, composicion farmaceutica que los comprende y uso para fabricar un medicamento para controlar citoquinas inflamatorias |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103549A AR037502A1 (es) | 2001-09-20 | 2002-09-20 | Compuesto de 6,7-dihidro-5h-pirazolo[1,2a]pirazol-1-ona espirociclico y su uso para fabricar una composicion farmaceutica |
| ARP020103550A AR037237A1 (es) | 2001-09-20 | 2002-09-20 | Compuesto de pirazolo de anillo fusionado, composicion que lo comprende y su uso para fabricar dicha composicion |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US6821971B2 (es) |
| EP (3) | EP1427727B1 (es) |
| JP (3) | JP2005504082A (es) |
| KR (4) | KR20060036125A (es) |
| CN (3) | CN1250551C (es) |
| AR (3) | AR037502A1 (es) |
| AT (3) | ATE332901T1 (es) |
| AU (2) | AU2002327690B2 (es) |
| BR (3) | BR0212716A (es) |
| CA (3) | CA2461072A1 (es) |
| CO (3) | CO5560589A2 (es) |
| CY (1) | CY1106398T1 (es) |
| CZ (3) | CZ2004345A3 (es) |
| DE (3) | DE60202782T2 (es) |
| DK (2) | DK1427732T3 (es) |
| EG (2) | EG24413A (es) |
| ES (3) | ES2282459T3 (es) |
| HU (3) | HUP0402378A3 (es) |
| IL (3) | IL160682A0 (es) |
| MA (3) | MA27065A1 (es) |
| MX (3) | MXPA04002569A (es) |
| MY (2) | MY129329A (es) |
| NO (2) | NO20041594L (es) |
| NZ (3) | NZ531122A (es) |
| PE (3) | PE20030446A1 (es) |
| PL (3) | PL370415A1 (es) |
| PT (3) | PT1427732E (es) |
| RU (3) | RU2272040C2 (es) |
| SA (1) | SA03230529B1 (es) |
| SK (3) | SK1492004A3 (es) |
| WO (3) | WO2003024973A1 (es) |
| ZA (3) | ZA200401260B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6849627B2 (en) | 2001-09-20 | 2005-02-01 | The Procter & Gamble Company | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| US7087615B2 (en) | 2001-09-20 | 2006-08-08 | The Procter & Gamble Company | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia |
| US6730668B2 (en) * | 2001-09-20 | 2004-05-04 | The Procter & Gamble Company | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| US7473695B2 (en) * | 2001-10-22 | 2009-01-06 | Mitsubishi Tanabe Pharma Corporation | 4-imidazolin-2-one compounds |
| US6677337B2 (en) * | 2002-03-19 | 2004-01-13 | The Procter & Gamble Company | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines |
| US6967254B2 (en) * | 2002-09-09 | 2005-11-22 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| US7557102B2 (en) * | 2003-04-03 | 2009-07-07 | Merck Patent Gmbh | Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor Xa inhibitors for the treatment of thromboses |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| US7482356B2 (en) * | 2003-11-10 | 2009-01-27 | The Procter & Gamble Company | Bicyclic pyrazolone cytokine inhibitors |
| BRPI0710507A2 (pt) * | 2006-04-18 | 2011-08-16 | Abbott Lab | Antagonistas do receptor vanilóide de subtipo 1 (vr1) e usos destes |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| KR20120016247A (ko) * | 2009-05-19 | 2012-02-23 | 다우 아그로사이언시즈 엘엘씨 | 진균 방제를 위한 화합물 및 방법 |
| EP3308059B1 (en) | 2015-06-15 | 2021-05-26 | Cummins, Inc. | Combustion chamber elasticity device |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| CN107033090B (zh) * | 2017-05-16 | 2019-05-07 | 无锡捷化医药科技有限公司 | 一种1,2,3,4-四氢噌啉的制备方法 |
| RU2721684C1 (ru) * | 2019-09-06 | 2020-05-21 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | Метил 2,3,8-триоксо-4-фенилтетрагидро-6Н-пиразоло[1,2-а]пирроло[2,3-c]пиразол-9а(1Н)-карбоксилаты |
| WO2023076133A1 (en) * | 2021-10-27 | 2023-05-04 | Merck Sharp & Dohme Llc | Spirotricycle ripk1 inhibitors and methods of uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1054291A (es) * | 1963-02-26 | |||
| GB1124982A (en) * | 1965-02-09 | 1968-08-21 | Lepetit Spa | Diazabicyclo octanes and derivatives thereof |
| CH529154A (fr) | 1969-10-27 | 1972-10-15 | Lepetit Spa | Procédé de préparation de pyrazolo (1,2-b) phtalazine-1,5 (10H)-diones |
| US5358924A (en) * | 1991-03-21 | 1994-10-25 | Bayer Aktiengesellschaft | 3-hydroxy-4-aryl-5-oxo-pyrozoline derivatives, compositions and use |
| KR100281450B1 (ko) * | 1992-05-15 | 2001-02-01 | 슈테펜 엘. 네스비트 | 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 신규 메르캅토아세틸아미도 피리다조[1,2]피리다진, 피라졸로[1,2]피리다진, 피리다조[1,2-a][1,2]디아제핀 및 피라졸로[1,2-a][1,2]디아제핀 유도체 |
| GB9303993D0 (en) * | 1993-02-26 | 1993-04-14 | Fujisawa Pharmaceutical Co | New heterocyclic derivatives |
| DK1481970T3 (da) * | 1999-09-07 | 2006-07-31 | Syngenta Participations Ag | Nye herbicider |
| US6730668B2 (en) * | 2001-09-20 | 2004-05-04 | The Procter & Gamble Company | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
-
2002
- 2002-09-18 US US10/245,927 patent/US6821971B2/en not_active Expired - Fee Related
- 2002-09-18 US US10/246,499 patent/US6566357B1/en not_active Expired - Fee Related
- 2002-09-20 KR KR1020067006983A patent/KR20060036125A/ko not_active Ceased
- 2002-09-20 ES ES02763693T patent/ES2282459T3/es not_active Expired - Lifetime
- 2002-09-20 RU RU2004111806/04A patent/RU2272040C2/ru not_active IP Right Cessation
- 2002-09-20 MY MYPI20023518A patent/MY129329A/en unknown
- 2002-09-20 CN CNB028182294A patent/CN1250551C/zh not_active Expired - Fee Related
- 2002-09-20 MX MXPA04002569A patent/MXPA04002569A/es active IP Right Grant
- 2002-09-20 CN CNB028182286A patent/CN1257905C/zh not_active Expired - Fee Related
- 2002-09-20 NZ NZ531122A patent/NZ531122A/en unknown
- 2002-09-20 EP EP02763692A patent/EP1427727B1/en not_active Expired - Lifetime
- 2002-09-20 AR ARP020103549A patent/AR037502A1/es not_active Application Discontinuation
- 2002-09-20 IL IL16068202A patent/IL160682A0/xx unknown
- 2002-09-20 EP EP02763693A patent/EP1427728B1/en not_active Expired - Lifetime
- 2002-09-20 RU RU2004111803/04A patent/RU2299885C2/ru active
- 2002-09-20 PT PT02799017T patent/PT1427732E/pt unknown
- 2002-09-20 WO PCT/US2002/030133 patent/WO2003024973A1/en not_active Ceased
- 2002-09-20 PL PL02370415A patent/PL370415A1/xx not_active Application Discontinuation
- 2002-09-20 NZ NZ531063A patent/NZ531063A/en not_active IP Right Cessation
- 2002-09-20 CZ CZ2004345A patent/CZ2004345A3/cs unknown
- 2002-09-20 MY MYPI20023502A patent/MY129069A/en unknown
- 2002-09-20 BR BR0212716-4A patent/BR0212716A/pt not_active IP Right Cessation
- 2002-09-20 PE PE2002000924A patent/PE20030446A1/es not_active Application Discontinuation
- 2002-09-20 ES ES02799017T patent/ES2268154T3/es not_active Expired - Lifetime
- 2002-09-20 SK SK149-2004A patent/SK1492004A3/sk unknown
- 2002-09-20 PL PL02370362A patent/PL370362A1/xx not_active Application Discontinuation
- 2002-09-20 AT AT02799017T patent/ATE332901T1/de not_active IP Right Cessation
- 2002-09-20 DK DK02799017T patent/DK1427732T3/da active
- 2002-09-20 CZ CZ2004361A patent/CZ2004361A3/cs unknown
- 2002-09-20 SK SK148-2004A patent/SK1482004A3/sk unknown
- 2002-09-20 AR ARP020103550A patent/AR037237A1/es not_active Application Discontinuation
- 2002-09-20 CN CNB028183800A patent/CN1249066C/zh not_active Expired - Fee Related
- 2002-09-20 CA CA002461072A patent/CA2461072A1/en not_active Abandoned
- 2002-09-20 DE DE60202782T patent/DE60202782T2/de not_active Expired - Lifetime
- 2002-09-20 HU HU0402378A patent/HUP0402378A3/hu unknown
- 2002-09-20 AU AU2002327690A patent/AU2002327690B2/en not_active Ceased
- 2002-09-20 DE DE60213108T patent/DE60213108T2/de not_active Expired - Fee Related
- 2002-09-20 KR KR1020047004043A patent/KR100656126B1/ko not_active Expired - Fee Related
- 2002-09-20 PT PT02763692T patent/PT1427727E/pt unknown
- 2002-09-20 KR KR1020047004045A patent/KR100623879B1/ko not_active Expired - Fee Related
- 2002-09-20 JP JP2003528818A patent/JP2005504082A/ja active Pending
- 2002-09-20 IL IL16074202A patent/IL160742A0/xx unknown
- 2002-09-20 DK DK02763693T patent/DK1427728T3/da active
- 2002-09-20 AT AT02763693T patent/ATE356126T1/de not_active IP Right Cessation
- 2002-09-20 PE PE2002000923A patent/PE20030430A1/es not_active Application Discontinuation
- 2002-09-20 SK SK150-2004A patent/SK1502004A3/sk unknown
- 2002-09-20 PE PE2002000925A patent/PE20030474A1/es not_active Application Discontinuation
- 2002-09-20 ES ES02763692T patent/ES2237691T3/es not_active Expired - Lifetime
- 2002-09-20 DE DE60218704T patent/DE60218704T2/de not_active Expired - Lifetime
- 2002-09-20 AR ARP020103548A patent/AR037145A1/es unknown
- 2002-09-20 JP JP2003528820A patent/JP2005504083A/ja active Pending
- 2002-09-20 RU RU2004111805/04A patent/RU2278864C2/ru active
- 2002-09-20 IL IL16074102A patent/IL160741A0/xx unknown
- 2002-09-20 AT AT02763692T patent/ATE287887T1/de not_active IP Right Cessation
- 2002-09-20 AU AU2002334641A patent/AU2002334641B2/en not_active Expired - Fee Related
- 2002-09-20 JP JP2003528817A patent/JP2005504081A/ja active Pending
- 2002-09-20 BR BR0212905-1A patent/BR0212905A/pt not_active IP Right Cessation
- 2002-09-20 MX MXPA04002570A patent/MXPA04002570A/es active IP Right Grant
- 2002-09-20 CA CA002461071A patent/CA2461071A1/en not_active Abandoned
- 2002-09-20 HU HU0500752A patent/HUP0500752A2/hu unknown
- 2002-09-20 EP EP02799017A patent/EP1427732B1/en not_active Expired - Lifetime
- 2002-09-20 CA CA002461073A patent/CA2461073A1/en not_active Abandoned
- 2002-09-20 NZ NZ531123A patent/NZ531123A/en not_active IP Right Cessation
- 2002-09-20 BR BR0212673-7A patent/BR0212673A/pt not_active IP Right Cessation
- 2002-09-20 PL PL02370351A patent/PL370351A1/xx not_active Application Discontinuation
- 2002-09-20 HU HU0402500A patent/HUP0402500A3/hu unknown
- 2002-09-20 WO PCT/US2002/030135 patent/WO2003024971A1/en not_active Ceased
- 2002-09-20 PT PT02763693T patent/PT1427728E/pt unknown
- 2002-09-20 MX MXPA04002574A patent/MXPA04002574A/es active IP Right Grant
- 2002-09-20 CZ CZ2004358A patent/CZ2004358A3/cs unknown
- 2002-09-20 WO PCT/US2002/030134 patent/WO2003024970A1/en not_active Ceased
- 2002-09-20 KR KR10-2004-7004046A patent/KR20040035837A/ko not_active Ceased
- 2002-09-21 EG EG2002091039A patent/EG24413A/xx active
- 2002-09-21 EG EG2002091037A patent/EG24363A/xx active
-
2003
- 2003-01-26 SA SA3230529A patent/SA03230529B1/ar unknown
-
2004
- 2004-02-17 ZA ZA200401260A patent/ZA200401260B/en unknown
- 2004-02-20 ZA ZA200401403A patent/ZA200401403B/en unknown
- 2004-02-20 ZA ZA200401402A patent/ZA200401402B/en unknown
- 2004-03-09 CO CO04021424A patent/CO5560589A2/es not_active Application Discontinuation
- 2004-03-09 CO CO04021425A patent/CO5560590A2/es not_active Application Discontinuation
- 2004-03-10 MA MA27568A patent/MA27065A1/fr unknown
- 2004-03-10 MA MA27569A patent/MA27066A1/fr unknown
- 2004-03-10 MA MA27567A patent/MA27064A1/fr unknown
- 2004-03-12 CO CO04023010A patent/CO5560579A2/es not_active Application Discontinuation
- 2004-04-19 NO NO20041594A patent/NO20041594L/no not_active Application Discontinuation
- 2004-04-20 NO NO20041605A patent/NO20041605L/no not_active Application Discontinuation
-
2007
- 2007-03-20 CY CY20071100383T patent/CY1106398T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037145A1 (es) | Compuestos de 6,7-dihidro-5h-pirazolo[1,2-a]pirazol-1-onas, composicion farmaceutica que los comprende y uso para fabricar un medicamento para controlar citoquinas inflamatorias | |
| DE69507476D1 (de) | Farnesyl-transferase-inhibitoren, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen | |
| AR023823A1 (es) | Compuestos derivados de piperazina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos. | |
| DE60025343D1 (de) | Pharmazeutische verbindungen | |
| BRPI0407387A (pt) | Derivados de hexahidro-pirazino[1,2-a]pirimidin-4,7-diona substituìdos por nitrogênio, processos para a sua preparação e sua aplicação com medicamento | |
| AR012315A1 (es) | Derivados de ditiolan y el uso de los mismos en la fabricacion de un medicamento. | |
| SV2003000633A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7 | |
| ATE184029T1 (de) | Zwei polymerisierbare gruppen ein perfluoralkylenäthermakromer enthaltend | |
| BRPI0414570A (pt) | derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso | |
| AR008878A1 (es) | Antagonistas del receptor de vitronectina, un metodo para su preparacion, una composicion farmaceutica que los contiene y el uso de las mismas para la preparacion de un medicamento. | |
| BR9713126B1 (pt) | compostos derivados da piridin-2-il-metilamina, processo para sua preparaÇço, compostos intermediÁrios de sÍntese, uso de um composto, e, composiÇço farmacÊutica. | |
| BR0108395A (pt) | Derivados de pirrolopirimidinona, processos de preparação e uso | |
| MEP56908A (en) | Reconstitutable parenteral composition containing a cox-2 inhibitor | |
| PT892794E (pt) | Prodrogas de n-hidroximetil-talidomida aciladas de efeito imunomodulador | |
| AR008541A1 (es) | Nuevos compuestos derivados de aminofosfonatos, procedimiento para su preparacion, uso de los mismos para la preparacion de un medicamento,composicion farmaceutica utiles en el tratamiento de aterosclerosis | |
| GEP19991599B (en) | 1,3-Oxathiolane, Its Geometric and Optical Isomers, Mixtures Thereof, Their Pharma- ceutically Acceptable Derivatives and Methods for Their Obtaining, Pharmaceutical Compositions Containing Them and Methods for Their Obtaining | |
| AR011094A1 (es) | Medicamento que contiene quinoxalinas en triple combinacion y el uso de quinoxalinas en triple combinacion con inhibidores de proteasas e inhibidoresde transcriptasa como medicamento para el tratamiento del sida y/o de infecciones por hiv | |
| CO5160292A1 (es) | Composicion farmaceutica que contiene derivados de 2-tienil- imidazolo[4,5]piridina, util para el tratamiento de infeccio nes virales | |
| AR008543A1 (es) | Un compuesto de camptotecina, un medicamento, una composicion farmaceutica que lo comprende y el uso del compuesto. | |
| DK0649405T3 (da) | 22-en-25-oxa-derivater i D-vitaminserien, fremgangsmåde til fremstilling heraf, farmaceutiske præparater indeholdende disse derivater samt anvendelse af sådanne præparater som lægemidler. | |
| CO5150179A1 (es) | Derivados de n-etilpirimidin o (piridin)-2-(1,2-benzoisoxa- zol-3-il)-octahidro-2h-pirido[1,2-a]pirazina y sus composiciones farmaceuticas | |
| CO5080752A1 (es) | INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB | |
| YU46298A (sh) | Karbapenem antibakterijska jedinjenja, njihova upotreba u proizvodnji leka korisnog za tretiranje ili prevenciju bakterijske infekcije i farmaceutske kompozicije koje ih sadrže | |
| AR051797A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas | |
| AR032598A1 (es) | Oxazinquinolonas, una composicion farmaceutica y el uso de las mismas para preparar un medicamento utiles en el tratamiento de infecciones virales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |